EUCTR2006-005513-35-LT进行中（未招募）1 期
A Randomized, Double-Blind, Active-Controlled, Multicenter Study to Assess the LDL-C Lowering of Switching to a Combination tablet Ezetimibe/Simvastatin (10mg/20mg) compared to Rosuvastatin 10mg in patients with primary hypercholesterolemia and high cardiovascular risk and not adequately controlled with a prior statin treatment. (IN-CROSS). - IN-CROSS
Merck&co., Inc.0 个研究点目标入组 1,200 人开始时间: 2007年1月29日最近更新:
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 1,200
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •LDL-C level = 100 mg/dL (2.50 mmol/L) and = 190 mg/dl (4.9 mmol/L) (sample collected at visit 1)
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Patients with liver or kidney disease
研究者
相似试验
进行中（未招募）
1 期
A Randomized, Double-Blind, Active-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Canagliflozin Versus Sitagliptin in the Treatment of Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin and Sulphonylurea Therapy - CANTATA-D2Type 2 Diabetes MellitusEUCTR2010-020053-14-BEJanssen-Cilag International NV720
招募中
3 期
A study to check out the effectiveness and safety of Lumateperone as another treatment used together with the main treatment in the Treatment of Patients with Major Depressive DisorderCTRI/2023/10/059345Intra-Cellular Therapies, Inc.
招募中
3 期
A study to assess the effectiveness and safety of Lumateperone as another treatment used together with the primary treatment in the Treatment of Patients with Major Depressive DisorderCTRI/2023/04/051968Intra-Cellular Therapies, Inc
招募中
1 期
A study to assess the efficacy and safety of lumateperone in patients with major depressive disorderMedDRA version: 21.1Level: LLTClassification code: 10081270Term: Major depressive disorder Class: 10037175Major Depressive DisorderCTIS2023-503836-41-00Intra-Cellular Therapies Inc.470
进行中（未招募）
1 期
Effects and Safety of Test drug ZYN002, applied as a gel onto the skin of children and adolescents with a certain hereditary disease called Fragile X SyndromeEUCTR2021-002542-33-IEZynerba Pharmaceuticals, Inc.204